Compounders Research Compare

Grace Therapeutics, Inc.(GRCE)

Biotechnology · Princeton, NJ

$2.13+0.06 (+3.16%)

Delayed quote: Oct 6, 2026, 1:03 PM EDT

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

Princeton, NJ

5 employees

www.gracetx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Prashant Kohli

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:07:10.981Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:07:10.981Z.

Quote observation: 2026-10-06T17:03:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 34,582,305
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 13,756,000
TTM free cash flow · period ending 2026-06-30: -10,300,639

FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GRCE EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

GRCE Competitors' EV/FCF Ratio

Grace Therapeutics, Inc.

Current

Market Cap

$34.58M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Elutia Inc

Market Cap

$34.76M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BriaCell Therapeutics Corp.

Market Cap

$34.97M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Accuray Incorporated

Market Cap

$34.11M

EV/FCF Ratio

N/A

TTM Avg

17.34x

3Y Avg

44.12x

5Y Avg

46.63x

Aligos Therapeutics, Inc.

Market Cap

$33.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DocGo Inc.

Market Cap

$35.80M

EV/FCF Ratio

N/A

TTM Avg

1.82x

3Y Avg

3.39x

5Y Avg

16.62x

HeartBeam, Inc.

Market Cap

$33.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EUDA Health Holdings Limited

Market Cap

$33.24M

EV/FCF Ratio

N/A

TTM Avg

509.31x

3Y Avg

509.31x

5Y Avg

509.31x

Scilex Holding Company

Market Cap

$32.50M

EV/FCF Ratio

N/A

TTM Avg

13.12x

3Y Avg

13.45x

5Y Avg

13.45x

QT Imaging Holdings, Inc.

Market Cap

$35.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Grace Therapeutics, Inc. (GRCE)	$34.58M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$34.76M	N/A	N/A	N/A	N/A
BriaCell Therapeutics Corp. (BCTX)vs ›	$34.97M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$34.11M	N/A	17.34x	44.12x	46.63x
Aligos Therapeutics, Inc. (ALGS)vs ›	$33.66M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$35.80M	N/A	1.82x	3.39x	16.62x
HeartBeam, Inc. (BEAT)vs ›	$33.27M	N/A	N/A	N/A	N/A
EUDA Health Holdings Limited (EUDA)vs ›	$33.24M	N/A	509.31x	509.31x	509.31x
Scilex Holding Company (SCLX)vs ›	$32.50M	N/A	13.12x	13.45x	13.45x
QT Imaging Holdings, Inc. (QTI)vs ›	$35.42M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics